PatientsVille.com Logo

PULMONARY EMBOLISM and ZOCOR

PatientsVille

PULMONARY EMBOLISM Symptoms and Causes

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. Pulmonary embolism is a serious condition that can cause

  • Permanent damage to the affected lung
  • Low oxygen levels in your blood
  • Damage to other organs in your body from not getting enough oxygen

If a clot is large, or if there are many clots, pulmonary embolism can cause death.

Half the people who have pulmonary embolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. The goal of treatment is to break up clots and help keep other clots from forming.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for PULMONARY EMBOLISM

PULMONARY EMBOLISM treatment research studies

ZOCOR clinical trials, surveys and public health registries


Find Drug Side Effect reports



ZOCOR Side Effects

Rhabdomyolysis (1045)
Myalgia (844)
Blood Creatine Phosphokinase Increased (494)
Asthenia (430)
Muscular Weakness (393)
Renal Failure Acute (366)
Pain In Extremity (328)
Arthralgia (302)
Muscle Spasms (284)
Fatigue (263)
Myopathy (253)
Renal Failure (231)
Pain (228)
Dyspnoea (220)
Myocardial Infarction (202)
Myositis (201)
Nausea (196)
Alanine Aminotransferase Increased (184)
Chest Pain (179)
Dizziness (178)
Fall (128)
Aspartate Aminotransferase Increased (127)
Malaise (122)
Cerebrovascular Accident (120)
Diarrhoea (119)
Headache (104)
Back Pain (101)
Liver Function Test Abnormal (101)
Depression (100)
Abdominal Pain (95)
Gait Disturbance (93)
Blood Creatinine Increased (93)
Anxiety (92)
Abasia (91)
Vomiting (87)
Amnesia (86)
Abdominal Pain Upper (79)
Anaemia (78)
Coronary Artery Disease (76)
Insomnia (75)
Cardiac Failure Congestive (74)
Weight Decreased (73)
Dehydration (72)
Pyrexia (71)
Confusional State (70)
Paraesthesia (70)
Hypertension (69)
Pneumonia (69)
Rash (68)
Cardiac Disorder (67)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I was having frequent leg cramps. They worked their way from my foot up to my thigh. I just thought it was from stopping the use of muscle relaxers ( for a serious back and neck problem). I had forgotten about them and never mentioned it to either

How long does it take to get back to normal after taking Zocor. I had a major problem in November 2008 and it is now May 2009 and I am still having problems and testing. It has cost me a fortune and they still say it is not Zocor but I still believe

I am asking, does Levaxin a thyroid med. and Zantac antiacid, is it OK to take those at the same time

I have a frozen diagfram and shrinking lung. It affects my breathing and energy. Could this possibly be caused by Zocor as I was told by someone who also has this condition. I also have lots of muscle pain daily.&nbs

In Oct. 2009 I went to the Emergency Room of my local hospital for a shortness of breath as I was struggling to catch my breath. I was asked if I had chest pain and responded no, just difficulty breathing. I was given morphine, pr

Lip swelling, acute.

My father died suddenly of a pulmonary Embolism with no signs or symtoms. We are devasted.....but the one thing that keeps pulling on my heart strings is he was already on blood thinners for years after his quadrapal by pass 13 years ago. He has been

On the 12th dec2011 i nearly died from a p. e. that had been going on for some time.I had a saddle on my lungs.I was 10 days in hospital & was treated with continued oxygen,clexane injections,warfaring pills,paracetamol pills,antibiotics in

Urinary retention Is there a correlation between this and using a statin. Had this problem shortly after starting a simvistatin routine.

What's on your mind...I am two months post PE after a total knee revision. Then three bleeds into the knee (big hematoma). Week later bleed and fluid into an already bad right shoulder requiring hospitalization. I am improving, however sleep an ext

My father is suffrering from idiotypic Pulmonary Fibrosis. In medication he is taking Prednisone,Perfenodone and azathropine. he is now geeting bleeding from his nose.Can anybody inform me that this is just a side effect of any d

After a pulmunary embolism diagnosis in April 2010, I was put on Warfarin for 11 months ... I was taken off it 1 week ago... While on it I experienced extreme lethargy , difficulty concentrating, memory loss, dizziness, ongoing ch

After being discharged from eER I saw in my file that the doppler impression shows mild tricuspid regurgitation and mild pulmonary hypertension =-O scared should I be worried

Completed course of interferon and ribavirn for Hepititis C. Fell pregnant 5 months after completion of treatment and gave birth to a baby boy weighing 7.6 lbs. He has Trisomy 21. He was born with Persisitant Pulmonary hypertension and a VSD. I do no

Female 39 years old from Denmark. Was treated with Octostim as a test. After drug was administred i experience this: <span style='font-weight: bold;'><a href='http://sideeffects101.com/drug-side-effects/o/octostim-pulmonary-oedema.htm' rel='

Has any one found legal representation willing to pursue pulmonary embolis caused by avandia

Having suffered 3 dvt's, 1 pulmonary embolism, 1 stroke and 2 tis's, I was given Fragmin. I previously had been taking warfarin for about 20 yrs, this ceased to work. I am now told that I have Osteoporosis... I seem to remember along the way that

Hello, im using trabectedin in a few weeks, after using ifoosfamide+doxorrubicin to treat pulmonary methastasis or a synovial sarcoma i am concened about loosin my hair again because it means too much for a woman and is not easy to use a wig in summ

How long can one live with the diagnosis of pulmonary hypertension? I have seen 3 to 5 years but I have had it for well over 10.

Husband has been taking avodart for 3 years. Developed a tightness in lungs, dry, non-productive cough, lungs feel a burning sensation. Thorough heart echo tests done, stress test. chest x-ray, mri, blood work, pulmonary function tests all passed.

PULMONARY EMBOLISM Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Condition: Prostate Carcinoma
Interventions: Drug: Metformin;   Drug: Simvastatin
Outcome Measures: Efficacy, as measured by an improvement in PSA doubling time (PSADT) between baseline and 6 months, of the combination of metformin plus simvastatin in patients with recurrent prostate cancer following definitive treatment.;   Time to protocol-specified event for men treated with the combination of metformin plus simvastatin.;   Pattern of change in log PSA levels and PSA velocity over time during treatment with metformin plus simvastatin.;   Associations between changes in metabolic parameters (fasting glucose/insulin/lipid panel/leptin/adiponectin and others) with the pattern of change in log PSA levels.
2 Recruiting Safety of Simvastatin in LAM and TSC
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis Complex
Intervention: Drug: Simvastatin
Outcome Measures: Safety of simvastatin in the treatment of LAM-S and LAM-TS patients on a stable (for at least 3 months) dose of sirolimus or everolimus.;   FEV1, FVC, DLCO, VEGF-D, and QOL; signs of clinical benefit.
3 Not yet recruiting Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Conditions: Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: Simvastatin;   Drug: Doxorubicin/cyclophosphamide
Outcome Measures: Change in echocardiographic Global Longitudinal Strain (GLS);   Number of participants with adverse events as a measure of safety and tolerability;   Recurrence free survival (RFS) with concurrent simvastatin
4 Unknown  Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: Simvastatin
Outcome Measure: Progression free survival
5 Recruiting Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Diabetes Mellitus, Type 2;   Hypertriglyceridemia
Interventions: Drug: Fenofibrate;   Drug: Simvastatin
Outcome Measures: Percentage change from baseline in triglycerides (TG) at week 12;   Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 12;   Percentage changes from baseline in apoB/apoA1 ratio at week 12;   Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 12;   Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 12;   Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 12;   Percentage changes from baseline in uric acid at week 12;   Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 52;   Percentage changes from baseline in apoB/apoA1 ratio at week 52;   Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 52;   Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 52;   Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 52;   Percentage changes from baseline in uric acid at week 52
6 Recruiting The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma
Condition: Asthma
Interventions: Drug: Simvastatin;   Drug: B1-6-12
Outcome Measures: Sputum eosinophils;   Phosphorylated p38 MAPK in sputum cells
7 Recruiting Stroke Treatment With Acute Reperfusion and Simvastatin
Condition: Stroke, Acute
Intervention: Drug: Simvastatin
Outcome Measures: The primary outcome of this study is to determine whether simvastatin treatment started within the first 12 hours from stroke onset improves neurological and functional outcomes, evaluated at seventh day/discharge or at the third month.;   The secondary outcome of this study is to demonstrate that simvastatin is safe and not associated with higher rates of hemorrhagic transformation in patients who receive thrombolysis.
8 Recruiting Simvastatin Addition for Patients With Recent-onset Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder;   Psychosis NOS
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measures: Change in Positive And Negative Syndrome Scale (PANSS) total score;   Change in PANSS positive, negative and general psychopathology scale scores;   Change in Global Assessment of functioning scale (GAF) score;   Change in cognitive functioning;   Presence and severity of metabolic syndrome;   Change in presence and severity of movement disorders using validated scales
9 Recruiting Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment
Condition: Rhinosinusitis
Intervention: Drug: SIMVASTATIN
Outcome Measures: Sino-Nasal symptomatology;   Bacterial culture;   Assessemt of liver and kidney functions;   RNA measurement of inflammatory biomarkers;   Sinus-Specific Quality of Life (22 questions Sino-nasal outcome test; SNOT-22);   Aspect of sinus mucosa aspect assessed by sinus endoscopy
10 Recruiting Effects of Simvastatin on Biomarkers
Condition: Alzheimer's Disease
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measures: Cerebral Spinal Fluid Biomarker measurements;   Measures of inflammation or oxidative stress in cerebral spinal fluid.
11 Not yet recruiting The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia
Condition: Choroideremia
Intervention: Drug: Simvastatin
Outcome Measures: Full-field scotopic threshold;   Microperimetry, OCT, fundus autofluorescence, ERG, VA
12 Unknown  Simvatstatin Used to Treat Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: simvastatin
Outcome Measures: the simvastatin can alleviate pulmonary hypertension;   pulmonary pressure;   simvastatin can highten the perioperative and long term survaval rate and the living quality
13 Recruiting Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: Simvastatin
Outcome Measures: Vaso-occlusive pain events;   Correlation of plasma biomarkers with clinical measures of vaso-occlusive pain;   Clinical safety of simvastatin
14 Unknown  Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.
Conditions: Diabetes Mellitus;   Hypertension
Interventions: Drug: atrorvastatin 10mg;   Drug: simvastatin 40mg
Outcome Measures: Reduction in oxLDL levels;   Reduction in plasma malondialdehydes and urine isoprostanes;   Reduction in plasma endothelial function parameters such as soluble Vascular Adhesion Molecule (sVCAM) and von Willebrand factor
15 Unknown  Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)
Conditions: Dyslipidemia;   Atherosclerosis
Interventions: Drug: simvastatin;   Drug: Nicotinic Acid
Outcome Measures: change of carotid and femoral IMT from baseline to 6 and 12 months follow up and occurrence of major adverse cardiovascular events (MACE);   changes of grey scale median (GSM) score from baseline to follow-up, and changes of serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides and lipoprotein (a).
16 Recruiting Simvastatin Augmentation of Lithium Treatment in Bipolar Depression
Condition: Bipolar Disorder
Interventions: Drug: Simvastatin;   Drug: Placebo
Outcome Measure: Change in MADRS (4 weeks)
17 Unknown  Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
Conditions: Cystic Fibrosis;   Anti Inflammatory Non-Steroidal;   Neutrophils
Interventions: Drug: Pioglitazone;   Drug: Simvastatin;   Drug: Ibuprofen
Outcome Measure: Neutrophil delivery to the oral mucosa using a noninvasive mouth wash technique
18 Recruiting Simvastatin for mTBI
Condition: TBI-Traumatic Brain Injury
Interventions: Drug: simvastatin;   Drug: placebo
Outcome Measures: cerebrospinal fluid (CSF) tau concentration;   Concentration of cerebrospinal fluid (CSF) Brain-derived neurotrophic factor (BDNF)
19 Recruiting Sarilumab Effect on the Pharmacokinetics of Simvastatin
Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88);   Drug: simvastatin
Outcome Measures: Assessment of PK parameters - area under curve from zero time until the last measurable concentration (AUClast) and AUC for simvastatin;   Assessment of PK parameters - maximum concentration (Cmax), time to maximum concentration (tmax), and terminal half-life associated with the terminal slope (t1/2z) for simvastatin;   Assessment of PK parameters - Cmax, AUClast, AUC, tmax, t1/2z for simvastatin acid;   Number of participants with adverse events
20 Recruiting Simvastatin Effect on Radiation Therapy of Brain Metastases
Condition: Brain Metastases
Interventions: Drug: simvastatin in addition to radiation therapy;   Radiation: radiation therapy
Outcome Measures: a- Response rate;   progression free and overall survival;   adverse effects